NBIO
Nascent Biotech, Inc.
Price Chart
Latest Quote
$0.00
+0.00 (+0.00%)
Current Price
| Previous Close | $0.00 |
| Open | $0.00 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 15,000 |
Stock Information
| Shares Outstanding | 172.22M |
| Total Debt | $59K |
| Cash Equivalents | $47K |
| Net Income | $-1.92M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $86K |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $98K |
| Income | $-1.92M |
| Book/sh | $-0.00 |
| Cash/sh | $0.00 |
Financial Ratios
| Quick Ratio | 0.06 |
| Current Ratio | 0.31 |
Returns & Margins
| ROA | -854.34% |
Ownership
| Insider Ownership | 21.51% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.17 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.00 |
| SMA50 | $0.00 |
| SMA200 | $0.00 |
| RSI | 66.67 |
| ATR | 0.0000 |
| Shares Float | 135.39M |
| Volatility | 1.76 |
Performance History
| Week | +25.00% |
| Month | -93.51% |
| Quarter | +25.00% |
| 6 Months | -44.44% |
| YTD | -16.67% |
| Year | +150.00% |
| 3 Years | -99.15% |
| 5 Years | -99.37% |
| 10 Years | -99.87% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $0.00 | 0 |
| 2026-06-22 | $0.00 | 0 |
| 2026-06-18 | $0.00 | 16,100 |
| 2026-06-17 | $0.00 | 1,053 |
| 2026-06-16 | $0.00 | 0 |
| 2026-06-15 | $0.00 | 0 |
| 2026-06-12 | $0.00 | 0 |
| 2026-06-11 | $0.00 | 0 |
| 2026-06-10 | $0.00 | 0 |
| 2026-06-09 | $0.00 | 0 |
| 2026-06-08 | $0.00 | 0 |
| 2026-06-05 | $0.00 | 0 |
| 2026-06-04 | $0.00 | 0 |
| 2026-06-03 | $0.00 | 0 |
| 2026-06-02 | $0.00 | 1,000 |
| 2026-06-01 | $0.00 | 0 |
| 2026-05-29 | $0.00 | 0 |
| 2026-05-28 | $0.00 | 0 |
| 2026-05-27 | $0.00 | 0 |
| 2026-05-26 | $0.00 | 600 |
About Nascent Biotech, Inc.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.
đ° Latest News
No news articles available at the moment. Check back later for updates on NBIO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $1,000,000 | $750,000 |
| Operating Revenue | $0 | $0 | $1,000,000 | $750,000 |
| Expenses | ||||
| Interest Expense | $385,236 | $1,723,148 | $335,983 | $336,632 |
| Total Expenses | $2,229,879 | $2,155,757 | $1,457,052 | $2,150,368 |
| Other Income Expense | $522,168 | $1,082,786 | $473,823 | $797,644 |
| Net Non Operating Interest Income Expense | $-379,971 | $-1,727,998 | $-487,121 | $-356,038 |
| Interest Expense Non Operating | $385,236 | $1,723,148 | $335,983 | $336,632 |
| Operating Expense | $2,229,879 | $2,155,757 | $1,457,052 | $2,150,368 |
| Other Operating Expenses | $411,973 | $383,688 | $332,289 | - |
| General And Administrative Expense | $1,706,931 | $1,501,540 | $927,357 | $1,828,430 |
| Total Other Finance Cost | - | $5,124 | $151,150 | $19,411 |
| Other Non Operating Income Expenses | - | - | - | $-369 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Net Interest Income | $-379,971 | $-1,727,998 | $-487,121 | $-356,038 |
| Interest Income | $5,265 | $274 | $12 | $5 |
| Normalized Income | $-2,609,850 | $-3,883,755 | $-944,213 | $-1,756,780 |
| Net Income From Continuing And Discontinued Operation | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Total Operating Income As Reported | $-2,229,879 | $-2,155,757 | $-457,052 | $-1,400,368 |
| Net Income Common Stockholders | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Net Income | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Net Income Including Noncontrolling Interests | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Net Income Continuous Operations | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Pretax Income | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Special Income Charges | $50,000 | $28,000 | $5,000 | $151,308 |
| Interest Income Non Operating | $5,265 | $274 | $12 | $5 |
| Operating Income | $-2,229,879 | $-2,155,757 | $-457,052 | $-1,400,368 |
| Per Share | ||||
| Diluted EPS | $-0.01 | $-0.02 | $-0.00 | $-0.01 |
| Basic EPS | $-0.01 | $-0.02 | $-0.00 | $-0.01 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,224,614 | $-2,160,607 | $-608,230 | $-1,420,148 |
| Total Unusual Items | $522,168 | $1,082,786 | $473,823 | $798,013 |
| Total Unusual Items Excluding Goodwill | $522,168 | $1,082,786 | $473,823 | $798,013 |
| EBITDA (Bullshit earnings) | $-1,702,446 | $-1,077,821 | $-134,407 | $-622,135 |
| EBIT | $-1,702,446 | $-1,077,821 | $-134,407 | $-622,135 |
| Diluted Average Shares | $155,744,233 | $118,569,028 | $107,741,761 | $72,342,193 |
| Basic Average Shares | $155,744,233 | $118,569,028 | $107,741,761 | $72,342,193 |
| Diluted NI Availto Com Stockholders | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Other Special Charges | $-50,000 | $-28,000 | $-5,000 | $-151,308 |
| Gain On Sale Of Security | $472,168 | $1,054,786 | $468,823 | $646,705 |
| Research And Development | $110,975 | $270,529 | $197,406 | $321,938 |
| Selling General And Administration | $1,706,931 | $1,501,540 | $927,357 | $1,828,430 |
| Other Gand A | $1,706,931 | $1,501,540 | $927,357 | $1,828,430 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-256,674 | $-1,296,137 | $-671,476 | $-472,505 |
| Total Assets | $552,120 | $255,002 | $105,414 | $751,435 |
| Total Non Current Assets | $0 | $0 | $0 | $0 |
| Current Assets | $552,120 | $255,002 | $105,414 | $751,435 |
| Prepaid Assets | $180,000 | $82,816 | $11,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $372,120 | $172,186 | $94,414 | $1,435 |
| Cash And Cash Equivalents | $372,120 | $172,186 | $94,414 | $1,435 |
| Cash Financial | $372,120 | $172,186 | $94,414 | $1,435 |
| Receivables | - | - | $0 | $750,000 |
| Accounts Receivable | - | - | $0 | $750,000 |
| Debt | ||||
| Total Debt | $122,500 | $389,591 | - | $161,736 |
| Current Debt And Capital Lease Obligation | $122,500 | $389,591 | - | $161,736 |
| Current Debt | $122,500 | $389,591 | - | $161,736 |
| Other Current Borrowings | $122,500 | $389,591 | - | $161,736 |
| Net Debt | - | $217,405 | - | $160,301 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $808,794 | $1,551,139 | $776,890 | $1,223,940 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $808,794 | $1,551,139 | $776,890 | $1,223,940 |
| Payables And Accrued Expenses | $686,294 | $498,122 | $776,890 | $760,048 |
| Payables | $686,294 | $498,122 | $776,890 | $760,048 |
| Accounts Payable | $686,294 | $498,122 | $776,890 | $636,831 |
| Other Current Liabilities | - | $663,426 | - | $302,156 |
| Current Notes Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-256,674 | $-1,296,137 | $-671,476 | $-472,559 |
| Total Equity Gross Minority Interest | $-256,674 | $-1,296,137 | $-671,476 | $-472,505 |
| Stockholders Equity | $-256,674 | $-1,296,137 | $-671,476 | $-472,505 |
| Retained Earnings | $-24,260,457 | $-21,622,775 | $-18,821,806 | $-18,351,416 |
| Preferred Stock Equity | - | - | - | $54 |
| Other | ||||
| Treasury Shares Number | $0 | - | - | - |
| Ordinary Shares Number | $170,594,165 | $131,764,348 | $111,313,175 | $104,834,083 |
| Share Issued | $170,594,165 | $131,764,348 | $111,313,175 | $104,834,083 |
| Tangible Book Value | $-256,674 | $-1,296,137 | $-671,476 | $-472,559 |
| Invested Capital | $-134,174 | $-906,546 | $-671,476 | $-310,823 |
| Working Capital | $-256,674 | $-1,296,137 | $-671,476 | $-472,505 |
| Total Capitalization | $-256,674 | $-1,296,137 | $-671,476 | $-472,505 |
| Additional Paid In Capital | $23,833,189 | $20,194,874 | $18,039,017 | $17,774,023 |
| Capital Stock | $170,594 | $131,764 | $111,313 | $104,888 |
| Common Stock | $170,594 | $131,764 | $111,313 | $104,834 |
| Preferred Stock | $0 | $0 | $0 | $54 |
| Dueto Related Parties Current | - | - | $0 | $123,217 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-1,186,066 | $-1,787,228 | $413,479 | $-986,784 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,186,066 | $-1,787,228 | $413,479 | $-986,784 |
| Cash Flow From Continuing Operating Activities | $-1,186,066 | $-1,787,228 | $413,479 | $-986,784 |
| Operating Gains Losses | $-472,168 | $-1,054,786 | $-468,823 | $-798,013 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $1,561,000 | $0 | $0 | $640,000 |
| Financing Cash Flow | $1,386,000 | $1,865,000 | $-320,500 | $985,000 |
| Cash Flow From Continuing Financing Activities | $1,386,000 | $1,865,000 | $-320,000 | $985,000 |
| Net Common Stock Issuance | $1,561,000 | $0 | - | - |
| Common Stock Issuance | $1,561,000 | $0 | - | - |
| Net Other Financing Charges | - | - | $-500 | - |
| Net Preferred Stock Issuance | - | - | $0 | $640,000 |
| Preferred Stock Issuance | - | - | $0 | $640,000 |
| Other | ||||
| Repayment Of Debt | $-400,000 | $-275,000 | $-520,000 | $0 |
| Issuance Of Debt | $225,000 | $1,932,000 | $200,000 | $345,000 |
| Interest Paid Supplemental Data | $0 | $11,135 | $30,027 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $372,120 | $172,186 | $94,414 | $1,435 |
| Beginning Cash Position | $172,186 | $94,414 | $1,435 | $3,218 |
| Changes In Cash | $199,934 | $77,772 | $92,979 | $-1,783 |
| Proceeds From Stock Option Exercised | $0 | $208,000 | $0 | - |
| Net Issuance Payments Of Debt | $-175,000 | $1,657,000 | $-320,000 | $345,000 |
| Net Short Term Debt Issuance | $-175,000 | $1,657,000 | $-320,000 | $295,000 |
| Short Term Debt Payments | $-400,000 | $-275,000 | $-520,000 | $0 |
| Short Term Debt Issuance | $225,000 | $1,932,000 | $200,000 | $295,000 |
| Change In Working Capital | $163,784 | $-317,335 | $911,176 | $-102,518 |
| Change In Payables And Accrued Expense | $260,968 | $-245,519 | $172,176 | $647,482 |
| Change In Prepaid Assets | $-97,184 | $-71,816 | $-11,000 | $0 |
| Change In Receivables | $0 | $0 | $750,000 | $-750,000 |
| Changes In Account Receivables | $0 | $0 | $750,000 | $-750,000 |
| Other Non Cash Items | $327,909 | $1,629,542 | $325,431 | $86,662 |
| Stock Based Compensation | $882,091 | $756,320 | $116,085 | $785,852 |
| Gain Loss On Investment Securities | $-472,168 | $-1,054,786 | $-468,823 | $-646,705 |
| Net Income From Continuing Operations | $-2,087,682 | $-2,800,969 | $-470,390 | $-958,767 |
| Change In Payable | - | $-245,519 | $172,176 | $647,482 |
| Change In Account Payable | - | $-245,519 | $167,060 | $230,401 |
| Net Long Term Debt Issuance | - | - | $0 | $50,000 |
| Long Term Debt Payments | - | - | $-520,500 | $0 |
| Long Term Debt Issuance | - | - | $0 | $50,000 |
Fetched: 2026-02-02